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The semi-invariant natural killer T cell receptor (NKT
TCR) recognizes CD1d-lipid antigens. Although the
TCRa chain is typically invariant, the b chain expres-
sion is more diverse, where three Vb chains are
commonly expressed in mice. We report the struc-
tures of Va14-Vb8.2 andVa14-Vb7NKTTCRs in com-
plexwithCD1d-a-galactosylceramide (a-GalCer) and
the 2.5 A˚ structure of the human NKT TCR-CD1d-a-
GalCer complex. Both Vb8.2 and Vb7 NKT TCRs
and the human NKT TCR ligated CD1d-a-GalCer in
a similar manner, highlighting the evolutionarily con-
served interaction. However, differences within the
Vb domains of the Vb8.2 and Vb7 NKT TCR-CD1d
complexes resulted in altered TCRb-CD1d-mediated
contacts andmodulated recognitionmediated by the
invariant a chain. Mutagenesis studies revealed the
differing contributions of Vb8.2 and Vb7 residues
within the CDR2b loop in mediating contacts with
CD1d. Collectively we provide a structural basis for
the differential NKT TCR Vb usage in NKT cells.
INTRODUCTION
Natural killer T (NKT) cells are a unique lymphocytic sublineage
that recognize lipid-based antigens presented by CD1d, a major
histocompatibility complex (MHC) class I-like antigen (Ag)-pre-
sentingmolecule (Bendelac et al., 2007). NKTcells are implicated
in a broad range of diseases, includingmicrobial immunity, tumor
immunity, autoimmunity, and allergy (Bendelac et al., 2007; God-
frey and Kronenberg, 2004; Matsuda et al., 2008). NKT cells are
present in mice and humans, and typically express a semi-
invariant T cell receptor (NKT TCR) consisting of an invariant
TCRa chain (Va24Ja18 in humans; Va14Ja18 in mice), paired
with a limited selection of TCRb chains (Vb11 in humans; Vb8.2,
Vb7, or Vb2 in mice) (Burdin et al., 1998; Godfrey et al., 2004;Porcelli et al., 1993). The restricted NKT TCR repertoire is consid-
ered to reflect their recognition of the monomorphic CD1d mole-
cule presenting glycolipid antigens. The crystal structure of
a human NKT TCR-CD1d-glycolipid (a-galactosylceramide;
a-GalCer) complex provided a snapshot into the basis of NKT
recognition and revealed a markedly different mode of TCR
recognition in comparison to that observed for TCR-MHC-
peptide complexes (Borg et al., 2007). In contrast to the emerging
generalities of the TCR-MHC-peptide interaction (Godfrey et al.,
2008; Rudolph et al., 2006), the NKT TCR docked parallel to, and
at the extreme end of, the CD1d-Ag binding cleft. Within this
unusual NKT TCR-CD1d docking framework, interactions with
CD1d were dominated by the complementarity determining
region (CDR) 3a loop encoded by Ja18 and Vb11-encoded
CDR2b loop, whereas the CDR1a and CDR3a loops contacted
the a-GalCer (Borg et al., 2007). Alanine-scanning mutagenesis
studies in the human Vb11 NKT TCR and mouse Vb8.2 NKT
TCRwere consistentwith thisNKTTCR-CD1d-a-GalCer docking
footprint (Scott-Browne et al., 2007;Wunet al., 2008), suggesting
a remarkable conservation of this immune recognition event
across the 70 million years of evolution that separate mice and
humans. For instance, two tyrosine residues (Tyr48b and
Tyr50b) conserved in the human Vb11 and mouse Vb8.2 CDR2b
loop were critical for NKT TCR-CD1d binding (Scott-Browne
et al., 2007; Wun et al., 2008), suggesting that the Vb8.2 NKT
TCR docked in a very similar manner to that of the human NKT
TCR, which was consistent with the reciprocal cross-species
reactivity of these NKT TCRs (Brossay et al., 1998). Structural
studies of a-GalCer bound to human and mouse CD1d also
revealed a broadly comparable landscape for NKT TCR binding
(Koch et al., 2005; Zajonc et al., 2005), but nevertheless differ-
ences were apparent in the orientation of the a-galactose head
grouppresentedbyCD1d from the twodifferent species (Godfrey
et al., 2005). It is unclear how the NKT TCRwould accommodate
such differenceswhenmediating cross-species reactivity.More-
over, it is just as unclear how different NKT TCRs might afford
differential reactivity to the same or different glycolipid antigens.
It is established that NKT cells can see an array of different
lipid-based antigens (reviewed in Bendelac et al., 2007;Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc. 47
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Mouse NKT TCR-CD1d-a-GalCer ComplexesBrutkiewicz, 2006; Godfrey et al., 2008), including bacteria-
derived lipid antigens (Fischer et al., 2004; Kinjo et al., 2005,
2006; Mattner et al., 2005) and mammalian (self)-glycolipid anti-
gens that include isoglobotrihexosylceramide (iGb3) (Zhou et al.,
2004) and GD3 (Wu et al., 2003). Notably, with the exception of
a-GalCer, most other glycolipid antigens seem to be recognized
with high affinity by only a subset of NKT cells (Brigl et al., 2006;
Kinjo et al., 2006, 2008; Wu et al., 2003). For example, CD1d
tetramers loaded with a-diacylglycerol (Kinjo et al., 2006), a-gal-
acturonosylceramide (Kinjo et al., 2005), or GD3 (Wu et al., 2003)
provided a spectrum of staining of NKT cells from negative to
bright positive, whereas a-GalCer-loaded CD1d tetramers
stained the same population with uniformly high intensity (Kinjo
et al., 2005, 2006; Wu et al., 2003). Similarly, iGb3 seems only
to be able to stimulate a subset of a-GalCer-reactive NKT cells
(Brigl et al., 2006; Zhou et al., 2004). Although this suggests
that antigen-specific subsets of NKT cells may exist, some
NKT TCRs are nevertheless capable of recognizing several dis-
tinct glycolipid antigens similarly (Scott-Browne et al., 2007;Mal-
levaey et al., 2009 [this issue of Immunity]), albeit with varying
affinity. Given that the NKT TCRa chain is invariant, this suggests
that NKT TCRb chain plays a role in determining thresholds of
antigen reactivity and that this effectively enables some NKT
TCRs to differentiate between antigens. This issue is particularly
relevant to mouse NKT cells, which possess a more diverse
TCRb repertoire than humans, because of the frequent use of
three Vb genes (Vb8.2, Vb7, and Vb2), in which Vb8.2- and
Vb7-containing NKT TCRs represent up to 80% of the mouse
NKT cell repertoire. Although human NKT cells also exhibit
some TCRb chain diversity, only a small subset lack Vb11
(Gadola et al., 2002), and furthermore, both human and mouse
NKT cells have diverse CDR3b regions (Gadola et al., 2002; Mat-
suda et al., 2001). In the mouse NKT system, several studies
support the differential contribution of TCRb chains to recogni-
tion of different lipid based antigens: a-GalCer is preferentially
recognized by NKT cells bearing Vb8.2 (Schumann et al.,
2003), whereas iGb3 is preferentially recognized by NKT cells
bearing Vb7 (Schumann et al., 2006; Wei et al., 2006). Further-
more, although mutations in the CDR3b region of the mouse
NKT TCR did not substantially affect a-GalCer-mediated activa-
tion of NKT TCR-expressing hybridomas, they markedly influ-
enced activation by other antigens, including iGb3 and GSL-1
(Scott-Browne et al., 2007). Thus, in order to understand how
NKT cells can recognize glycolipid antigens, and the selective
Vb gene usage by NKT cells, we need to gain a more complete
picture of the different NKT TCRs in complex with CD1d-Ag.
Here we have determined the structures of the Vb8.2 and Vb7
NKT TCRs in complex with mouse CD1d-a-GalCer and
compared them to a new 2.5 A˚ resolution structure of the human
Vb11 NKT TCR-CD1d-a-GalCer complex. Our findings, together
with associated mutagenesis studies, provide insight into how
the Vb repertoire of NKT TCRs impacts on CD1d-glycolpid
recognition.
RESULTS
Vb8.2 NKT TCR-CD1d-a-GalCer Complex
To begin to address the varied Vb usage inmouse NKT TCRs, we
expressed and refolded the Va14Ja18-Vb8.2 and Va14Ja18-48 Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc.Vb7 NKT TCRs (Figures S1A and S1B available online), then
formed and crystallized the complex with the mouse (m)CD1d-
a-GalCer. The structure of the Va14Ja18-Vb8.2 NKT TCR-
mCD1d-a-GalCer complex was subsequently determined to
2.9 A˚ resolution to anRfac andRfree of 23.4% and 29.8%, respec-
tively (Table S1). The initial experimental phases clearly showed
unbiased electron density for the a-GalCer and moreover, apart
from a small disordered (on account of mobility of the loop)
region within the CDR3b loop (residues Gly98b to Glu105b),
the electron density at the Va14-Vb8.2 NKT TCR-mCD1d-a-
GalCer interface was unambiguous.
Both the Vb8.2 and Vb7 NKT TCRs adopted an acute dock-
ing mode, binding approximately parallel to, and above, the
F’-pocket of the CD1d-Ag binding cleft (Figures 1A–1D). The
Vb8.2 NKT TCR will be discussed first. This TCR interacted
with mCD1d residues spanning 76–87 and 149–153 of the a1
helix and the a2 helix, respectively. The buried surface area
(BSA) upon ligation was z760 A˚2, in which the TCRa chain
contributes nearly three times more BSA than the TCRb chain
(74% versus 26%, respectively) (Figure 1C), which is consistent
with the a chain dominating contacts with CD1d-a-GalCer in
comparison to the b chain (Figure 2A; Table 1). The Vb8.2 chain
usage was dictated by the CDR2b loop interacting with mCD1d,
as indicated by the fact that the CDR1b loop does not mediate
any contacts with the Ag and the CDR3b loop was mobile
(Table 1). The CDR2b loop formed a stretch of interactions exclu-
sively with the a1 helix (residues 83–87) of mCD1d (Table 1;
Figure 1C). Specifically, Tyr48b and Tyr50b formed H bonds
and Van der Waals (VDW) contacts with Glu83 and Lys86 of
CD1d, the latter of which formed a salt bridge with Glu56b
(Figure 2B).
The Va14-Ja18 a chain interactions were mediated via the
CDR3a and CDR1a loops (57% and 17% BSA, respectively)
(Figures 2A and 2C; Table 1). The CDR1a loop interacted with
a-GalCer, whereas the Ja18-encoded CDR3a loop interacted
with mCD1d and a-GalCer. The importance of the Ja18-
encoded region is consistent with the lack of NKT cells in TCR
Ja18 gene-inactivated mice (Cui et al., 1997). The CDR3a-medi-
ated interactions were largely electrostatic in nature, but also
included some VDW-mediated contacts, including Leu99a that
sat in a small hydrophobic niche, formed by Leu84, Leu150,
Val149 of mCD1d, but made contacts with only the latter residue
(Figure 2A). There was an interdigitation of arginine residues at
the CDR3a-mCD1d interface, in which Arg79 from CD1d was
flanked by Arg103a and Arg95a. This cluster of positively
charged residues were dissipated by neighboring acidic groups,
including Asp94a, which salt bridged to Arg79; Arg103a that salt
bridged to Glu83; and Arg95a that salt bridged to Asp80
(Figure 2A). Additionally, the main chain amide of Gly96a H
bonded to Asp153 of mCD1d and as such, all Ja18 residues at
the tip of the CDR3a loop, with the exception of Ala98a, medi-
ated contacts with mCD1d-a-GalCer (Table 1).
Only the galactose head group of a-GalCer is exposed for
recognition by the NKT TCR, and interacted solely with the
CDR1a and CDR3a loops (Figure 2C; Table 1). The galactose
ring sat below the CDR1a loop and adjacent to the CDR3a
loop, forming VDW contacts on one face of the sugar ring with
Arg95a, Gly96a, and Pro28a. Arg95a also made VDW contacts
with the 30 hydroxyl of the sphingosine chain (Figure 2C).
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Mouse NKT TCR-CD1d-a-GalCer ComplexesGly96a H bonds to the 20 hydroxyl, whereas Asn30a H bonds to
both the 30 and 40 hydroxyl groups of the galactose ring. As such,
the galactose ring is sequestered closely by the invariant a chain
of the Vb8.2 NKT TCR.
The crystal structure of the Vb8.2 NKT TCR-mCD1d-a-GalCer
complex also allowed us to undertake precise structural corre-
A
D E F
B C Figure 2. Mouse CD1d and a-GalCer Medi-
ated Interactions with Mouse NKT TCRs
CDR3a mediates multiple contacts between
mCD1d a helices and a-GalCer. CDR2b contacts
a1 helix of mCD1d. CDR1a interacts solely with
a-GalCer galactose head group. CDR1bmediates
polar interactions with the a2 helix only in Vb7 NKT
TCR-mCD1d-a-GalCer.
(A) Vb8.2 NKT TCR CDR3a contacts with mCD1d.
(B) Vb8.2 NKT TCR CDR2b contacts with mCD1d.
(C) Vb8.2 NKT TCR CDR1a and CDR3a contacts
with a-GalCer.
(D) Vb7 NKT TCR CDR3a contacts with mCD1d.
(E) Vb7 NKT TCR CDR1b, CDR2b, and CDR3b
contacts with mCD1d.
(F) Vb7NKT TCRCDR1a andCDR3a contactswith
a-GalCer. CDR1a, purple; CDR3a, yellow; CDR1b,
teal; CDR2b, ruby; CDR3b, orange; a-GalCer,
magenta; mCD1d, gray. H bond or salt bridge
interactions are shown in black dashed lines.
A
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Figure 1. Structure of Mouse NKT TCRs in Complex
with Mouse CD1d-a-GalCer
(A) Va14-Vb8.2 NKT TCR in complex with mCD1d-a-GalCer.
a-GalCer, magenta; mCD1d heterodimer, gray; TCRa chain,
cyan; Vb8.2 NKT TCRb chain, green; CDR1a, purple;
CDR3a, yellow; CDR1b, teal; CDR2b, ruby; CDR3b, orange;
mobile CDR3b region, dashed orange.
(B) Va14-Vb7 NKT TCR in complex with mouse CD1d-a-
GalCer. Vb7 NKT TCRb chain, blue; TCRa chain, mCD1d;
CDR loops and a-GalCer color coding as in (A).
(C) Footprint of the Va14-Vb8.2 NKT TCR on the surface of
mouse CD1d-a-GalCer. a-GalCer is shown in spheres.
mCD1d, a-GalCer, and CDR loops color coding as in (A).
(D) Footprint of the Va14-Vb7 NKT TCR on the surface of
mCD1d-a-GalCer. a-GalCer is shown in spheres. mCD1d,
a-GalCer, and CDR loops color coding as in (A).
lates of the alanine-scanning mutagenesis study
previously conducted in this system (Scott-Browne
et al., 2007). We can confirm that the effect of
some of the Vb8.2 NKT TCR mutants in interacting
with mCD1d-a-GalCer are due to indirect local
effects (namely, CDR1a: Val26Ala, Pro28Ala, As-
n30Ala, His31Ala, Arg33Ala; CDR1b: Asn31Ala;
CDR2b: Ser49Ala; Gly51Ala). In contrast, the
mutational data are in accord with the crystal
structure: namely the CDR1a, CDR3a, and CDR2b
loops represent the energetic footprint of the inter-
action with mCD1d-a-GalCer. Accordingly, the
structure of the Vb8.2 NKT TCR-mCD1d-a-GalCer
complex provided a basis for understanding the
biased gene usage of the semi-invariant Va14Ja18-Vb8.2
NKT TCR.
Conformational Changes upon Ligation
The mCD1d-PBS-25 (an analog of a-GalCer with modifications in
the lipid chains) and an engineered variant of Va14Ja18-Vb8.2Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc. 49
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Mouse NKT TCR-CD1d-a-GalCer ComplexesTable 1. Contacts at the mNKT TCR-mCD1d Interface
CDR Vb8.2 NKT mCD1d Bond Vb7 NKT mCD1d Bond
CDR3a Asp94Od1 Arg79Nh1, Arg79Nh2 salt bridge Asp94Od1 same as Vb8.2
Asp94Od2 Arg79Nh1, Arg79Nh2 salt bridge Asp94Od2 same as Vb8.2
Asp94 Arg79 VDW Asp94 same as Vb8.2
Arg95N3 Asp80Od1, Asp80Od2 salt bridge Arg95N3 same as Vb8.2
Arg95Nh1 Asp80Od1 salt bridge Arg95Nh1 Asp80Od1, Asp80Od2 salt bridge
Ser76Og H bond
Arg95 Asp80, Arg79, Ser76 VDW Arg95 same as Vb8.2
Gly96N Asp153Od2 H bond Gly96N -
Gly96 Ala152, Asp153 VDW Gly96 same as Vb8.2
Ser97 Val149 VDW Ser97 Val149, Ala152, Asp153 VDW
Leu99 Arg79, Val149 VDW Leu99 Arg79, Asp80, Glu83, Leu84,
Val149, Leu150
VDW
Leu99 Arg79Nh2 H bond Leu99 -
Gly100 Arg79 VDW Gly100 -
Arg103 Arg79, Glu83 VDW Arg103 Arg79 VDW
Arg103Nh1 Glu83O32, Glu83O31 salt bridge Arg103Nh1 -
CDR1b - Glu30O32 Lys148Nz salt bridge
- Glu30 Lys148 VDW
CDR2b Tyr48Oh Glu83O31, Glu83O32, Lys86Nz H bond -
Tyr48 Glu83, Lys86 VDW -
Tyr50Oh Glu83O31 H bond Tyr50Oh same as Vb8.2
Tyr50 Glu83, Met87 VDW Tyr50 same as Vb8.2
- Ser54 Met87, Leu145 VDW
Glu56O31 Lys86Nz salt bridge Ser56Og Glu83O31 H bond
Glu56 Lys86 VDW Ser56 Glu83, Lys86 VDW
CDR3b - Thr97 Ala152 VDW
- Gly98 Ala152 VDW
CDR Vb8.2 NKT a-GalCer Bond Vb7 NKT a-GalCer Bond
CDR1a Pro28 60-OHG, 50-OG, C-1G VDW Pro28 same as Vb8.2
Asn30 C-2G, C-3G, C-4G, 30-OHG, 40-OHG VDW Asn30 -
Asn30Nd2 30-OHG, 40-OHG H bond Asn30Nd2 same as Vb8.2
CDR3a Asp94 C-1G VDW Asp94 same as Vb8.2
Arg95 20-OHG, C-2G, 30-OHS VDW Arg95 same as Vb8.2
Gly96N 20-OHG H bond Gly96N same as Vb8.2
Gly96 C-2G, 30-OHG VDW Gly96 C-2G, 30-OHG, 20-OHG VDW
Atomic contacts determined with the CCP4i implementation of CONTACT and a cutoff of 4.5 A˚.
Van der Waals interactions defined as nonhydrogen bond contact distances of 4 A˚ or less.
Hydrogen bond interactions are defined as contact distances of 3.3 A˚ or less.
Salt bridge is defined as contact distance of 4.5 A˚ or less.
G= contacts with Galactose head group.
S= contacts with Sphingosine chain.NKT TCR (which included mutations at the Va-Vb interface and
within the invariant CDR3a loop) have been solved in the nonli-
ganded state (Zajonc et al., 2005, 2008). Hence we evaluated the
degreeof plasticity in this Vb8.2NKTTCR-mCD1d-a-GalCer inter-
action by comparing the elements of the complex in their liganded
and unliganded state. The CDR loops of the Vb8.2 NKT TCR did
not change conformation appreciably upon ligation to mCD1d-a-
GalCer, although movements in some side chains (Asn30a,
Tyr48b, andTyr50b) were observed (data not shown). Interestingly,
upon Vb8.2 NKT TCR ligation, the a-GalCer head group was50 Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc.observed tobeshiftedbyapproximately1 A˚ (FigureS2). Incompar-
ison to the nonliganded Vb8.2 NKT TCR (Zajonc et al., 2008),
there was a slight change in the juxtapositioning (9.5) of the
Va14 and Vb8.2 domains upon ligation. Notably, suchmovements
have been observed previously in TCR-pMHC interactions, where
they are thought to relate to signal transmission (Ishizuka et al.,
2008).
In addition, there was minimal movement in the mCD1d upon
ligation, with some reorientation of side-chain conformations
observed including Arg79, Glu83, Lys86, and Lys148 from
Immunity
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Figure 3. Comparison of Va14-Vb8.2, Va14-
Vb7, and Va24-Vb11 NKT TCR-mCD1d-a-
GalCer Complexes
(A) Superposition of Va14-Vb8.2 NKT TCR-
mCD1d-a-GalCer and Va14-Vb7 NKT TCR-
mCD1d-a-GalCer. Differences in the relative juxta-
positioning of the Vb8.2-Vb7 and Va14 domains.
TCRa chain, cyan; Vb8.2 NKT TCRb chain, green;
Vb7 NKT TCRb chain, blue; a-GalCer, magenta;
mCD1d, gray.
(B) Differences in the sequence of CDR2b in Vb8.2
and Vb7 NKT TCR affected the position of Arg103a
in the CDR3a loop and subsequently altered
positions and contacts of Arg79, Asp80, Ser76,
and Arg95a. Va14-Vb8.2 NKT TCR-mCD1d-a-
GalCer, pink; Va14-Vb7 NKT TCR-mCD1d-a-
GalCer, yellow. a-GalCer is shown in ball and stick.
H bond or salt bridge interactions are shown in
black dashed lines, and VDW interactions are
shown in red dashed lines.
(C) Altered position of Tyr50b in Vb7 NKT TCR
affected contacts made by Ser97a and Leu99a
at the tip of CDR3a with mCD1d. Color coding as
in (B). H bonds are shown in black dashed lines
and VDW interactions are shown in red dashed
lines.
(D) Conserved interactions mediated by CDR1a,
CDR3a, and CDR2b loops of the human and
mouse NKT TCRs on the surface of CD1d and
a-GalCer. CDR1a, purple; CDR2b, ruby; CDR3a,
yellow; a-GalCer, magenta; CD1d, gray. The
numbering shown on CD1d is according to the
mouse CD1d. H bonds or salt bridge interactions
are shown in black dashed lines.
(E) The shift in the position of the galactose head
group of a-GalCer between mouse and the human
NKT TCR-CD1d-a-GalCer structures is due to the
presence of a bulky tryptophan side chain in
human CD1d (Trp153) in contrast to glycine
(Gly155, shown in yellow) in mouse CD1d. Human
CDR1a, salmon; mouse CDR1a, purple; a-GalCer
in human, marine; a-GalCer in mouse, magenta;
hCD1d, pale green; mCD1d, gray.mCD1d (data not shown). Overall, the lack of conformational
change upon Vb8.2 NKT TCR-mCD1d-a-GalCer ligation, which
was also observed in the human NKT TCR-CD1d-a-GalCer
interaction (Borg et al., 2007; Kjer-Nielsen et al., 2006), typifies
the innate characteristics of this interaction mediated by a
relatively ‘‘rigid’’ receptor-ligand binding, whereas TCRs typi-
cally show a greater degree of plasticity upon ligation with
pMHC.
Vb7 NKT TCR-CD1d-a-GalCer Complex
The Va14Ja18-Vb7 NKT TCR is expressed by approximately
15%–20% of the mouse NKT T cell repertoire (Benlagha et al.,
2000; Matsuda et al., 2000), and the Vb7 and Vb8.2 chains share
54% sequence identity, with sequence differences located in the
CDR1b and CDR2b loops (Figure S3). Accordingly, we also
aimed to understand how the Vb7 NKT TCR interacted with
mCD1d-a-GalCer. Hence, the refolded Va14-Vb7 NKT TCR
(Figure S1) complexed to mCD1d-a-GalCer was crystallized
and the structure determined to 2.8 A˚ resolution with an Rfac
and Rfree of 22.4% and 27.1%, respectively (Table S1). The initialexperimental phases clearly showed unbiased electron density
for a-GalCer, and the electron density at the Va14-Vb7 NKT
TCR-mCD1d-a-GalCer interface was unambiguous.
Like the Vb8.2 NKT TCR-CD1d-a-GalCer complex, the Va14-
Vb7 NKT TCRwas perched above the F’-pocket of the CD1d-Ag
binding cleft, interacting with a similar stretch of residues on
mCD1d (76–87 and 145–153) (Figures 1D and 2D–2F). The foot-
print of the two TCRs were very similar, with the Va contacts
being dictated by the CDR1a and CDR3a loops, the former
exclusively contacting a-GalCer and the latter making substan-
tial contacts with both mCD1d and a-GalCer. However, within
these common footprints, there were notable differences in the
contacts made between the Vb7 and Vb8.2 NKT TCRs and
CD1d-a-GalCer, attributable to sequence differences between
the NKT TCRs and differing relative juxtapositioning of the
Vb8.2 and Vb7 domains with respect to the Va14 domains
(Figures 3A and 3B). In turn, these differences also altered the
nature of some of the Va14-Ja18-mCD1d-a-GalCer interactions
(Figures 3B and 3C; Table 1), despite the commonality of the
invariant a chain between the two NKT TCRs.Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc. 51
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NKT TCRandmCD1d (z860 A˚2; Figure 1D) than the correspond-
ing Vb8.2 NKT TCR-mCD1d-a-GalCer footprint (Figure 1C). This
was attributable to a differing juxtapositioning of Va14 and Vb7
(9) compared with that of Va14-Vb8.2 NKT TCR, which resulted
in the Vb7 domain being positioned closer to mCD1d (Figure 3A),
and hence resulted in more contacts with CD1d when compared
to the Vb8.2 NKT TCR (Table 1). Consequently, the Va14 chain
contributes 59% BSA and the Vb7 chain 41% BSA at the Vb7
NKT TCR-CD1d-a-GalCer interface.
The Vb7 chain interacted only with mCD1d, and although the
majority of contacts were mediated via the CDR2b loop (27%
BSA), the CDR3b (9% BSA) loop and surprisingly the CDR1b
loop (3% BSA) also mediated contacts with mCD1d (Figure 1D).
Specifically, as a result of the Vb7 chain leaning more toward the
mCD1d in comparison to Vb8.2, this permitted a salt bridge to be
formed betweenGlu30b (Asn30b in Vb8.2) and Lys148 (Figure 2E).
The interactionswith theCDR3b loopwere via Thr97b andGly98b,
both of which abutted against Ala152 of mCD1d, and this interac-
tion presumably aided in stabilizing the CDR3b loop. The interac-
tions with the Vb7 CDR2b loop were featured by Tyr50b, which
lay flat against Met87 of mCD1d, forming a H bond with Glu83,
the latter of which also formed a H bond with Ser56b (Figure 2E).
Although Tyr50b and its interactions with CD1d are conserved
between Vb7 and Vb8.2, the relative position of Tyr50b varies in
the two complexes (Figure 3C). In addition, Ser54b formed VDW
interactions with Met87 and Leu145. The small side chains of
Ser54b and Ser56b were able to contact mCD1d as a result of
the CDR2b chain being closer to mCD1d when compared to the
corresponding CDR2b loop of the Vb8.2 chain (Figure 3A).
Structural differences at the Va14-Vb7 and Va14-Vb8.2 inter-
faces also ‘‘transmitted’’ to alterations in some of the Va14-
Ja18-mCD1d contacts (Figure 3B). Specifically, although many
of the a chain-mediated contacts were similar (Table 1), differ-
ences in Ja18-mediated contacts were observed at the tip of the
CDR3a loop, namely residues Asp94a, Arg95a, Gly96a, Ser97a,
Leu99a, and Arg103a. First, these changes appeared to emanate
from an altered contact between Arg103a and the respective Vb
chains. Thus, in the Vb8.2 NKT TCR, Arg103a stretches between
the Va-Vb interface, with its guanadinium group being tethered
by Tyr48b, which enabled Arg103a to salt bridge to Glu83 of
mCD1d. InVb7,however, position48 isoccupiedbyan Ile residue,
which does not contact mCD1d, andmoreover results in a loss of
interaction with Arg103a, causing Arg103a to swing away from
theVa-Vb interface andpack against Arg79 ofmCD1d (Figure 3B).
This in turn affects the conformation of Arg95a and Asp80 of
mCD1d, the latter of which H bonds to a-GalCer in Vb8.2 and
Vb7. The altered conformation of Arg95a in Vb7NKT TCR resulted
in loss of an H bond interaction with Ser76 of mCD1d (Table 1).
Second, the altered position of Tyr50b in Vb8.2 and Vb7 NKT
TCRs (Figure 3C) also pushed the tip of the CDR3a loop away
from CD1d, thereby altering the interactions this region made
withmCD1d-a-GalCer (Table 1). For example, this changecaused
Leu99a to sit differently within the hydrophobic mCD1d niche,
which in turn results in Leu99a and Ser97a forming more VDW
contacts in the Vb7 NKT TCR when compared to the Vb8.2 NKT
TCR-mCD1d-a-GalCer interface (Figure 3C; Table 1).
Accordingly, although the overall Vb8.2 and Vb7 NKT TCR-
mCD1d-a-GalCer structures were similar, the Vb7 domain52 Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc.played a more prominent role at the interface and also affected
the invariant a chain-CD1d contacts.
Comparison to the Human NKT TCR-CD1d-aGalCer
Complex
Previously, we had determined the structure of the human NKT
TCR-CD1d-a-GalCer complex to 3.2 A˚ resolution,making it chal-
lenging to accurately assign subtle structural changes that may
be present between differing NKT TCR-CD1d-Ag complexes.
Accordingly, the human NKT TCR-CD1d-a-GalCer complex
was crystallized in a different space group to that originally
reported (Borg et al., 2007) and the structure determined to 2.5 A˚
resolutionwith anRfacandRfreeof 21.6%and27.9%, respectively
(Table S1).We then compared the structure of the high-resolution
human NKT TCR-CD1d-a-GalCer complex to the two mouse
NKT TCR-CD1d-a-GalCer complexes to ascertain the evolution-
arily conserved characteristics of the NKT TCR-CD1d innate
interaction (Figure 3D; Figures S4A and S4B). Overall, the foot-
prints of the human and mouse NKT TCRs were similar, espe-
cially between the homologous Vb domains (Vb11 in humans
and Vb8.2 in mouse). Within this common footprint, the following
interactions were conserved between the three complexes:
Pro28a to a-GalCer; Asp94a to a-GalCer; Asp94a to Arg79;
Arg95a to a-GalCer; Arg95a to Asp80, Arg79, and Ser76;
Gly96a to a-GalCer; Gly96a to Asp153 (Asp151 in human
CD1d); Ser97a to Val149 (Val147 in human CD1d); Leu99a to
Val149; and Tyr50b to Glu83 and Met87 (Figure 3D).
Nonetheless, a number of differences at the NKT TCR-CD1d
interfaces between the three complexes were present, and these
were attributable to (1) altered Va-Vb juxtapositioning (approxi-
mately 13 to 15 rotation between human and mouse NKT
TCR-CD1d complexes), (2) sequence differences between the
respective CDR loops that mediated CD1d and a-GalCer recog-
nition, and (3) structural differences between hCD1d and
mCD1d, which included an altered positioning of the a-GalCer
galactose head group because of the presence of a neighboring
Trp153 (Gly155 in mCD1d) in hCD1d (Godfrey et al., 2005).
Nevertheless, the a-galactose head group was sequestered to
a similar extent in all three NKT TCR-CD1d-a-GalCer structures
(Figures 3D and 3E), with the preservation of the H bond interac-
tions to the 20, 30, and 40 hydroxyl groups.
Accordingly, the NKT TCR footprint on CD1d is broadly
comparable across species, highlighting the evolutionarily con-
served nature of this interaction. Nevertheless, differences at
the NKT TCR-CD1d interfaces were observed, suggesting that
a degree of malleability in NKT TCR-CD1d recognition plays
a role in the reciprocal cross-species reactivity between the
human and mouse NKT TCRs.
Vb7 and Vb8.2 NKT TCR Binding Affinity
Given the differences in the binding of the human NKT TCR and
the mouse Vb8.2 and Vb7 NKT TCRs, we determined the affinity
and relative avidity of the interactions by using surface plasmon
resonance (SPR) and CD1d-a-GalCer tetramer inhibition
studies, respectively.
The affinity (equilibrium dissociation constant, KD) of Vb8.2
NKT TCR for mCD1d-a-GalCer was 70 nM, whereas the KD for
the Vb7 NKT TCR-mCD1d-a-GalCer interaction was at 0.3 mM
(Figures 4A and 4C; Table S2). These differing affinities were
Immunity
Mouse NKT TCR-CD1d-a-GalCer ComplexesFigure 4. Differential Binding Affinities of NKT TCRs to CD1d-a-GalCer
(A–D) Va14Ja18-Vb8.2 (A and B) and Va14Ja18-Vb7 (C and D) NKT TCR were injected over streptavidin-immobilized mouse (A and C) and human (B and D)
CD1d-a-GalCer and simultaneously over a control cell coated with unloaded CD1d. Sensograms show the binding (response units, RU) of increasing concen-
trations of TCR (0.01 to 1 mM for Va14Ja18-Vb8.2 and 0.05 to 5 mM for Va14Ja18-Vb7) to mouse and human CD1d-a-GalCer after baseline subtraction. Insets
show saturation plots demonstrating equilibrium binding of NKT TCR to immobilizedCD1d-a-GalCer. The equilibrium dissociation constants (KD) derived by equi-
librium analysis were equivalent to those derived by kinetic analysis.
(E) CD1d-a-GalCer tetramer inhibition. Recombinant soluble NKT TCRs were examined for their ability to block binding of mCD1d-aGC tetramers to mouse NKT
cells. PE-labeled CD1d-a-GalCer tetramers were preincubated with titrating amounts of soluble NKT TCRs or an irrelevant TCR control, LC13, before staining of
mouse thymocytes. Cells were analyzed by flow cytometry showing mCD1d-a-GalCer tetramer-PE on the vertical axis and anti-CD3 APC on the horizontal axis.
CD3+ mCD1d-a-GalCer tetramer+ thymic NKT cells are indicated within the square with the MFI (mean fluorescence intensity) indicated. All measurements were
taken in duplicate.Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc. 53
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Mouse NKT TCR-CD1d-a-GalCer Complexesattributable to much longer half life of the Vb8.2 NKT TCR (t1/2 =
17.3 s) compared to the Vb7 NKT TCR (t1/2 = 6.9 s) and were
consistent with previous affinity measurements determined via
CD1d-multimer staining (Mallevaey et al., 2009; Schumann et al.,
2003). Consistent with the reciprocal cross-species reactivity of
NKT cells, the Vb8.2 NKT TCR also bound human (h)CD1d-a-
GalCer (KD z 94 nM) with similar affinity to mCD1d-a-GalCer,
although the respective on and off rates were distinct (Figures 4A
and 4B; Table S2). In contrast, the Vb7NKT TCR bound hCD1d-a-
GalCer with approximately 12-fold lower affinity (KD z3.4 mM;
Figure 4D), which was consistent with hCD1d-a-GalCer dimer
preferentially detecting Vb8.2 NKT cells (Schumann et al., 2003).
Human NKT TCR affinity for hCD1d-a-GalCer was lower (KD z
0.2 mM) than that for the Vb8.2 NKT TCR-mCD1d-a-GalCer inter-
action (Table S2), and human NKT TCR bound with moderately
lower affinity tomCD1d-a-GalCer (KDz 1 mM), as observedprevi-
ously (Wun et al., 2008).
To cross-validate the binding affinity for the three NKT TCRs,
we used aCD1d-a-GalCer tetramer binding inhibition assay (Fig-
ure 4E; Kjer-Nielsen et al., 2006). The Vb8.2 NKT TCR blocked
tetramer binding with the highest efficiency, still readily detect-
able to a concentration of 0.98 mg/ml. In contrast, the Vb7 NKT
TCR was approximately 25% less effective and human NKT
TCR was 25% less effective again. This hierarchy is consistent
with the affinities of the different TCRs as determined by SPR
analysis. The negative control TCR, LC13 (anti-HLA-B8-FLR)
(Kjer-Nielsen et al., 2003), did not inhibit tetramer staining at
any of the doses tested.
Accordingly, these data are consistent with our SPR affinity
measurements, showing that Vb8.2 NKT TCRpreferentially inter-
acts with CD1d-a-GalCer when compared to Vb7 NKT TCR.
NKT TCR Mutagenesis
Given thediffering contactsmadeby theCDR2b loopof theVb8.2
and Vb7 NKT TCRs, we next established the importance of the
residues within these loops of the respective mouse NKT TCRs.
With the structures as a guide, we mutated CDR2b residues
that were observed to contact CD1d and examined the effect
of the mutants via SPR (Figures 5A–5F; Table S3) and CD1d-a-
GalCer tetramer inhibition studies (Figure 6). For the Vb8.2 and
Vb7 NKT TCRs, three (Tyr48bPhe, Tyr50bPhe, Glu56bAla) and
four (Tyr50bPhe, Ser54bAla, Ser56bAla, Glu57bAla) mutants
from the CDR2b loop were examined, respectively, and one
residue from the CDR1b loop served as a negative control
(Vb8.2, Asn28bAla; Vb7, Asp26bAla). All of the mutant NKT TCR
proteins behaved similarly to the WT NKT TCR in gel filtration
and analysis under reducing and nonreducing SDS-PAGE.
Furthermore, an ELISA study showed that the NKT TCR mutant
proteins were as reactive as the WT NKT TCR to conformation-
sensitive mAb reactive against the NKT TCR (data not shown).
NKT TCR substitutions that caused <50% change in the affinity
of the interaction with CD1d-a-GalCer compared to WT NKT
TCR were considered to have no major effect. Conversely, NKT
TCR substitutions that caused >50% change in binding affinity
were considered to be energetically important to the interaction.
As expected, the controlmutationswithin theCDR1b loopdid not
affect CD1d-a-GalCer binding (Figures 5E, 5F, and 6). In the
Vb8.2 NKT TCR, the Tyr48bPhe, Tyr50bPhe, and Glu56bAla
mutants impacted substantially on CD1d-a-GalCer recognition,54 Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc.consistent with previous alanine-scanning mutagenesis at posi-
tions 48 and 50 in the human Vb11 NKT TCR, although the corre-
sponding Glu56b position was shown not to be essential for the
human NKT TCR-CD1d-a-GalCer interaction. The conservative
Tyr48bPhe and Tyr50bPhe mutations revealed the importance
of their hydroxyl groups in mediating a series of polar contacts
with CD1d. In the Vb7 NKT TCR, Ser56b and Glu57bwere shown
not to be critical for the interaction,whereas Tyr50bwas shown to
play a major role in the interaction with CD1d, again highlighting
the importance of the aromatic residues in the CDR2b loop in
mediating CD1d contacts. Interestingly, the Ser54bAla mutation
in the Vb7 TCR was observed to markedly improve the affinity of
the interaction from 134 to 32.6 nM, making the affinity of this
mutant comparable to that of the wild-type Vb8.2 NKT TCR. A
similar result was observed in another study where CD1d
tetramer binding was used to determine TCR affinity (Mallevaey
et al., 2009). The effect of the Ser54bAla mutant can be attribut-
able to the Ser54Og group being uncompensated within a hydro-
phobic pocket (Table 1), and accordingly, the Ala mutant forms
more favorable VDW interactions when compared to the wild-
type counterpart. Thus, not all residues within the CDR2b loop
of theVb7NKTTCRareof the optimal chemistry andcomposition
to interactwithCD1d, and this, in part,may explainwhy the Vb8.2
NKT TCR interacts with CD1d-a-GalCer with a higher affinity
when compared to the Vb7 NKT TCR.
DISCUSSION
The Vb8.2 and Vb7 NKT TCR-mCD1d-a-GalCer structures, in
conjunction with the human NKT TCR-CD1d-a-GalCer struc-
ture, broadly supports earlier suggestions that the NKT TCR
exhibits characteristics of a pattern-recognition receptor (Scott-
Browne et al., 2007). Namely, the relatively rigid semi-invariant
NKT TCR interacts with a monomorphic Ag-presenting molecule
in an approximately conserved manner. Within this conserved
docking framework that was situated above the CD1d F’ pocket,
the invariant CDR1a loop and CDR3a loop contact a-GalCer
and CD1d-a-GalCer, respectively, whereas the Vb domain inter-
acted exclusively with CD1d. Although the NKT TCR is ‘‘innate-
like,’’ the NKT TCR Vb chain nevertheless exhibits diversity in the
CDR3b loop and the mouse NKT cell repertoire uses Vb8.2, Vb7,
and to a lesser extent Vb2 (Benlagha et al., 2000; Matsuda et al.,
2000). Our study addressed the basis and impact of this differ-
ential Vb usage when recognizing the prototypic NKT cell Ag,
a-GalCer. The Vb8.2 and Vb7 NKT TCRs interacted with CD1d
in a different manner as a result of sequence and structural
differences between these Vb domains. These differences
resulted in a greater involvement of the Vb7 chain interacting
with mCD1d when compared to the Vb8.2 chain, which included
the CDR1b loop of Vb7-mediating contacts with CD1d. In addi-
tion, the importance of specific residues, as directly judged by
mutagenesis data, within the respective CDR2b loops varied:
in Vb8.2 NKT TCR, Tyr48b, Tyr50b, and Glu56b were essential,
whereas only Tyr50b was critical in Vb7-mediated recognition
of CD1d. Surprisingly, the Ser54bAla mutant improved the
affinity of the Vb7 NKT TCR-CD1d-a-GalCer interaction mark-
edly, thereby revealing simultaneously that the sequence and
composition of the NKT TCR Vb7 CDR2b loop is nonideal for
interacting with CD1d, thereby providing insight into why the
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Mouse NKT TCR-CD1d-a-GalCer ComplexesVb8.2 NKT TCR interacts with CD1d-a-GalCer with higher
affinity than does Vb7 NKT TCR. Furthermore, despite the
invariant nature of Va14-Ja18, differences in the Vb domains
were ‘‘transferred’’ to the Ja18 chain, which impacted on
Ja18-mediated CD1d-a-GalCer recognition. Collectively, these
differences manifested in the Vb8.2 NKT TCR interacting with
mCD1d-a-GalCer with a moderately higher affinity compared
to the Vb7 NKT TCR.
The two mouse NKT TCR-CD1d-a-GalCer complexes,
together with the 2.5 A˚ human NKT TCR-CD1d-a-GalCer struc-
ture reported here, allowed us to evaluate the residues in this
interaction that are evolutionarily conserved. Namely, the con-
served NKT TCR residues that contact identical residues in
CD1d are Pro28a of the CDR1a loop; Asp94a, Arg95a, Gly96a,
Ser97a, and Leu99a of the CDR3a loop; and Tyr50b of the
CDR2b loop. However, given that the CDR2b loop of Vb2 does
A
C
E F
D
B Figure 5. Binding of Mutant NKT TCRs to
Mouse CD1d-a-GalCer as Assessed by
Surface Plasmon Resonance
(A–D) Wild-type Vb7 NKT TCR (A), Vb8.2 NKT TCR
(B), mutant Vb7 NKT TCR S54A (C), and mutant
Vb8.2 (Y48F) NKT TCR (D) were injected over
streptavidin-immobilized mouse CD1d-a-GalCer
and over a control cell containing unloaded
CD1d. Sensograms show the binding (response
units, RU) of decreasing concentrations of TCR
(5, 2, 0.8, 0.32, 0.13, and 0.05 for Va14Ja18-Vb7
TCRs and 1, 0.4, 0.16, 0.064, 0.026, and 0.01 mM
for Va14Ja18-Vb8.2 TCRs) to mouse CD1d-a-
GalCer after subtraction of the control flow cell.
Insets show saturation plots demonstrating equi-
librium binding of NKT TCR to immobilized
CD1d-a-GalCer.
(E and F) Binding of mutant NKT TCR to mouse
CD1d a-GalCer. Site-directed mutants of indi-
vidual Vb7 or Vb8.2 residues were refolded with
the invariant a chain. The data are presented as
a percentage binding of wild-type NKT TCR.
Experiments were conducted in duplicate for the
wild-type and for the following mutants: Vb7
S54A, S56A, E57A, and Vb8.2 N28A.
not contain any tyrosine residues, this
indicates the evolutionary conserved
‘‘interaction codon’’ that underlies
CD1d-restricted a-GalCer recognition by
the NKT TCR is encoded by the Va14-
Ja18 domain (Va24-Ja18 in humans).
Recently, conserved binding residues or
‘‘interaction codons’’ have been defined
for Vb8.2 TCRs ligating pMHC (Dai et al.,
2008; Feng et al., 2007). This observation
allows us to assess whether these resi-
dues adopt similar roles in MHC-re-
stricted and CD1d-restricted recognition
by Vb8.2 TCRs. Whereas the two Tyr resi-
dues forming ‘‘interaction codons’’ within
the CDR2b loop of Vb8.2 TCRs are used
in recognizing both MHC (Dai et al.,
2008; Feng et al., 2007) and CD1d
(Scott-Browne et al., 2007), they interact in markedly different
regions of these Ag-presenting molecules (Godfrey et al.,
2008), thereby highlighting the contrasting characteristics of
peptide- and glycolipid-mediated recognition.
Despite the restricted NKT TCR repertoire, NKT cells can
recognize a large array of CD1d-restricted lipid antigens
(reviewed in Bendelac et al., 2007; Brutkiewicz, 2006). Given that
the Vb domains can modulate the affinity for CD1d-Ags (Malle-
vaey et al., 2009), this suggests that any given Vb chain will be
an important factor in determining the range of Ags in which
any given NKT TCR can interact with. The structural differences
observed in the Vb8.2 and Vb7 NKT TCR recognition of mCD1d-
a-GalCer may contribute to modulating the affinity toward other
CD1d-restricted Ags. Moreover, the differences in CDR3b
sequence, structure, and their potential for interaction with
CD1d in the NKT TCR-CD1d-a-GalCer complexes indicate thatImmunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc. 55
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Consistent with this, Vb8.2+ NKT TCRs were shown to have
higher affinity for a-GalCer bound to mCD1d, whereas Vb7+
NKT TCRs have been reported to preferentially recognize iGb3
when compared to Vb8.2 NKT TCRs (Schumann et al., 2006;
Wei et al., 2006). However, the recent study (Mallevaey et al.,
2009) found that hybridomas expressing Vb8.2 NKT TCRs
recognize CD1d-iGb3 with higher affinity than those expressing
Vb7 NKT TCRs. This discrepancy might, at least in part, indicate
a key contribution by CDR3b regions to the recognition of iGb3
Figure 6. Binding of Mutant NKT TCRs as Assessed by CD1d-a-GalCer Tetramer Inhibition
Recombinant soluble NKT TCRs, and mutants thereof, were examined for their ability to block binding of mCD1d-a-GalCer tetramers to mouse NKT cells.
PE-labeled CD1d-a-GalCer tetramers were preincubatedwith titrating amounts of soluble wild-type andmutant NKT TCRs before staining of mouse thymocytes.
Cells were analyzed by flow cytometry showing mCD1d-a-GalCer tetramer-PE on the vertical axis and anti-CD3 APC on the horizontal axis. CD3+ mCD1d-a-
GalCer tetramer+ thymic NKT cells are indicated within the square with the MFI indicated.56 Immunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc.
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et al., 2006). Of potential interest, the sphingosine chain of
a-GalCer interacts with Leu84 of mCD1d, a residue that packs
against Leu99a of the CDR3a loop, the position of which and
extent of mCD1d contacts was differentially influenced by the
Vb8.2 and Vb7 usage. Accordingly, it suggests that different
length lipid tails may alter the Leu84-CDR3a loop contact,
thereby providing a subtle mechanism for NKT TCRs to ‘‘sense’’
various ligands differently (McCarthy et al., 2007). In this regard,
improving the resolution of the human NKT TCR-CD1d-a-Galcer
complex from 3.2 A˚ to 2.5 A˚ resolution is important, because it
will serve as a more accurate benchmark to evaluate the subtle
effects differing ligands may impart on the conformation of the
CD1d Ag-binding cleft, which in turn may effect NKT TCR recog-
nition. Plasticity in the NKT TCR-CD1d interaction is also sug-
gested by the altered positioning of the a-GalCer head group
between the human and mouse CD1d structures (Godfrey
et al., 2005). Although reciprocal cross species reactivity is
observed between the Vb8.2 and Vb11 NKT TCR, this is partly
diminished in the Vb7 NKT TCR. In addition, the a-GalCer head
group bound tomCD1dwas observed to be shifted when ligated
to the mouse NKT TCRs, which suggests that flexibility in the
sugar head group may play a role in the NKT TCR recognition
of other Ags, such as the bulky iGb3. Flexibility in the peptide
Ag has also been observed in a TCR-pMHC interaction (Tynan
et al., 2007). Indeed, a basic superposition of the mCD1d-iGb3
structure (Zajonc et al., 2008) onto our Vb8.2 NKT TCR-CD1d-
a-GalCer structure indicates that such flexibility may occur,
unless a significantly different binding mode exists between
Vb8.2 NKT TCR-mCD1d-a-GalCer and Vb8.2 NKT TCR-
mCD1d-iGb3, which seems less likely with the mutagenesis
data that suggest a similar docking mode for iGb3 and a-GalCer
(Mallevaey et al., 2009; Scott-Browne et al., 2007).
The different NKT TCRb chains reported here converge on
a common CD1d-antigen footprint, yet differences within these
footprints were evident. Thus, although the NKT TCR could be
considered as a pattern recognition receptor, our study reveals
the potential for greater diversity at the NKT TCR-CD1d inter-
face, thus providing greater scope for the differential recognition
of a broad variety of CD1d-restricted antigens.
EXPERIMENTAL PROCEDURES
Cloning and Expression of Genes Encoding the Mouse NKT Va14,
Vb8.2, and Vb7 TCRs
RNA was extracted from NKT-expressing mouse thymocytes (purified by flow
cytometric sorting of thymocytes stained with CD1d-a-GalCer tetramers) and
reverse transcribed. cDNAs encoding each the mouse NKT Va14, Vb8.2, and
Vb7 NKT TCRs were amplified by PCR and cloned into P-GEM Easy (Prom-
ega). We were unable to refold the intact ectodomains of mouse TCRs (data
not shown) and employed the use of the human constant domains of the
NKT TCR to aid in refolding. In brief, soluble chimeric mouse-human TCR
gene segments were then PCR generated by splicing by overlap extension
and transferred into the expression vector PET30 (Novagen). Stop codons
were inserted immediately before the codons encoding the cysteines naturally
forming alpha-beta interchain disulfide bonds. Instead, interchain disulfide
pairing was achieved through Thr48Cys and Ser57Cys mutations introduced
into the human alpha and beta constant domains, respectively. Each chimeric
gene was thus predicted to encode a soluble hybrid mouse-human NKT TCR
consisting of a mouse variable and a human constant domain, lacking a trans-
membrane and cytoplasmic domain.Soluble Va14-Vb8.2 and Va14-Vb7 NKT TCRs were expressed in BL21
E. coli, and inclusion body protein was prepared, refolded, and purified as
per the protocol of Garboczi et al. (1996), except protein was refolded in the
presence of either 1 M (Va14 and Vb8.2) or 5 M (Va14 and Vb7) urea. The func-
tional integrity of the NKT TCRs was confirmed by gel filtration, gel shift exper-
iments, and anti-TCR mAb ELISA reactivity (Figure S1).
Expression and Purification of CD1d
mCD1dwasproduced in-house as described previously (Matsuda et al., 2000).
In brief, mCD1d was made with a dual promoter baculovirus transfer vector,
pBacp10pH, kindly provided by M. Kronenberg (La Jolla Institute for Allergy
and Immunology, CA). Recombinant mCD1dwas producedwith a BirA tag fol-
lowed by a 6 amino acid histidine tag and expressed with HI5 insect cells.
Soluble mCD1d protein was purified with Ni-Agarose affinity purification and
subsequently passed over a Superdex 200 16/60 gel filtration column to
remove aggregated material. For making mCD1d tetramers or for coating Bio-
RadProteOnchips, purifiedmCD1dwasbiotinylatedwithBirA enzyme (Avidity)
as permanufacturer’s protocol. TheBirA andHis-tagwere not removed prior to
crystallization. Human CD1d was made in an analogous manner, with the
exception that it lacked a BirA tag. Human CD1d was biotinylated by biotin-
malemide treatment of a free cysteine residue at the C-terminal end.
Loading of CD1d
Loading of CD1d was carried out by incubating with a-GalCer (provided by
Kirin Brewery Co. and Alexis Biochemicals) in a 3:1 (lipid:protein) molar ratio
at room temperature overnight. Excess a-GalCer was removed from CD1d
via Superdex 200 10/300 gel filtration.
Complexation of NKT TCRs with CD1d-a-GalCer
Purified NKT TCR and a-GalCer-loaded CD1d were mixed, and the ternary
complex was isolated by gel filtration on a Superdex 200 16/60 column (GE
Healthcare), concentrated to 10 mg/ml, and used in crystal trials.
Flow Cytometry and CD1d-a-GalCer Tetramer Inhibition Assay
Anti-mouse TCRb-allophycocyanin (APC) (clone H57-597) and CD3-APC
(clone 145-2C11) were purchased from BD Biosciences. The CD1d-a-GalCer
tetramer inhibition assay was carried out as described previously (Kjer-Nielsen
et al., 2006). Thymocytes were prepared by gently grinding the organ between
frosted glass slides. Stained cells were analyzed by flow cytometry with
a FACScalibur flow cytometer (Becton Dickinson).
Crystallization, Structure Determination, and Refinement
The Vb8.2 NKT TCR-CD1d-a-GalCer (7 mg/ml in 10 mM Tris [pH 8.0] and
150 mM NaCl) and Vb7 NKT TCR-CD1d-a-GalCer (6 mg/ml in 10 mM Tris
[pH 8.0] and 150 mM NaCl) complex crystallized at room temperature in
17% polyethylene glycol 10K, 0.1 M ammonium acetate, 0.1 M BisTris
(pH 5.5) via the hanging drop vapor diffusion technique. Equal ratio of the
protein to mother liquor resulted in plate-like crystals after 2–3 days. The crys-
tals were flash frozen prior to data collection in mother liquor containing 20%
glycerol as the cryoprotectant. The crystals of Vb8.2 NKT TCR-CD1d-a-GalCer
and Vb7 NKT TCR-CD1d-a-GalCer complex diffracted to 2.9 A˚ and 2.8 A˚,
respectively, and belong to the space group P212121, with one ternary complex
in the asymmetric unit. The human NKT TCR-CD1d-a-GalCer (10 mg/ml in
10 mM Tris [pH 8.0] and 150 mM NaCl) complex crystallized at room temper-
ature in 10%–12% PEG 10K, 0.2 M magnesium chloride, 0.1 M Tris (pH 9.0).
The crystals were equilibrated in the precipitation solution with increasing
concentrations of PEG 10K to 35% for at least a few days. The dehydrated
crystals were flash frozen in the dehydration solution prior to data collection.
The humanNKT TCR-CD1d-a-GalCer diffracted to 2.5 A˚ resolution and belong
to the space group P2 with two ternary complexes in the asymmetric unit.
Data for the two mouse NKT TCR complexes were collected at the Austra-
lian Synchrotron Facility in Melbourne, Australia, and processed with
programs from the CCP4 suite (CCP4, 1994). The data for the human NKT
TCR-CD1d-a-GalCer were collected at the Advanced Photon Source synchro-
tron facility in Chicago and processed with HKL2000 and programs from the
CCP4 suite. The crystal structure of the Vb8.2 NKT TCR-CD1d-a-GalCer
was solved by the molecular replacement method with the program Phaser
from the CCP4 Suite. The structure of mouse CD1d-glycosphingolipidImmunity 31, 47–59, July 17, 2009 ª2009 Elsevier Inc. 57
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Mouse NKT TCR-CD1d-a-GalCer Complexescomplex (Protein Data Bank ID code 2FIK) minus the lipid and the structure of
unliganded semi-invariant Va14 TCR (Protein Data Bank ID code 2Q86) were
used as the search models for solving Vb8.2 NKT TCR-CD1d-a-GalCer.
Refmac in CCP4 suite was used for the initial round of rigid body refinement
and subsequently restrained refinement interspersed with rounds of model
building with Coot (Emsley and Cowtan, 2004). At a later stage of refinement,
restrained refinement included translation libration screw parameters. The
progress of refinement was monitored by the Rfree value. The Vb7 NKT TCR-
CD1d-a-GalCer was solved by the molecular replacement method in Phaser,
with Vb8.2 NKT TCR-CD1d-a-GalCer minus the lipid as the search model.
Initially, the structure was refined via rigid body refinement in Refmac followed
by the simulated annealing protocol implemented in Phenix (Zwart et al., 2008).
The model was improved with iterative rounds of refinement and model
building. Translation libration screw parameters were included at a later stage
of refinement and the progress of refinement wasmonitored by the Rfree value.
The human NKT TCR-CD1d-a-GalCer was solved by molecular replacement
method in Phaser, with the 3.2 A˚ structure solved previously (Protein Data
Bank ID code 2PO6) minus the lipid as the search model. The quality of the
three structures was assessed with the programs within CCP4. The residues
that could not be modeled in the Vb8.2 NKT TCR-CD1d-a-GalCer were:
CD1d, residues 1–7, 90–93, and 110; TCRa chain, residues 134–135 and
209–210; and TCRb chain, residues 1–2 and 98–105 (CDR3b). The residues
that could not be modeled in the Vb7 NKT TCR-CD1d-a-GalCer were:
CD1d, residues 1–7, 88–94, and 108–110; TCRa chain, residues 130–135,
186–187, and 208–210; and TCRb chain, residues 1 and 122. The residues
that could not be modeled in the human NKT TCR-CD1d-a-GalCer were:
CD1d, residues 1–5 for chain A and 1–4 for chain C; b2 m, residues 98–99
for chain B; TCRa chain, residues 131–132, 137, 154 for chain E and 136 for
chain G; and TCRb chain, residues 1, 100–101 for chain F and 1 for chain H.
For data collection and refinement statistics, see Table S1. All molecular
graphics representations were created with PyMol (DeLano, 2002).
Surface Plasmon Resonance
The interaction between soluble, recombinant CD1d andwild-type andmutant
NKT TCRs were analyzed by SPR with a Bio-Rad ProteOn XPR36 instrument
(Hercules, CA). All experiments were performed at 25C in a buffer containing
10 mMHEPES (pH 7.4), 150 mMNaCl, and 0.005% Tween-20 (HBS-T). Strep-
tavidin was diluted into 10 mM sodium acetate (pH 4.5), and 3000 RU was
immobilized on all 6 flow cells of a GLC Sensorchip (Bio-Rad) by amine
coupling. Biotinylated CD1d was passed over the surface of the chip and
700 RU was captured by the streptavidin. Flow cells 1 and 2 contained
a-GalCer-loaded mouse and human CD1d, respectively, whereas flow cells
3 and 4 contained empty mouse and human CD1d and served as control cells.
Recombinant wild-type and mutant NKT TCR was subjected to size-exclusion
chromatography within 24 hr of analysis and the concentration of purified
protein estimated by OD280. Wild-type and mutant NKT TCRs were then seri-
ally diluted from 5 mM to 0.05 mM or 1 mM to 0.01 mM in HBS-T and injected
simultaneously over the test and control surfaces at a flow rate of 30 mL/min.
After subtraction of data from control flow cells, the interactions were analyzed
with the ProteOnManager software version 2.1 (Bio-Rad) and steady-state KD
values were derived from the equilibrium option of the software package.
Kinetic data were derived with the kinetic fit option of the software and data
analysis was fitted with the 1:1 Langmuir binding model.
Probing Conformational Integrity of the Wild-Type
and Mutant NKT TCRs
100 ml of soluble NKT TCR (5 mg/ml) was added to a 96-well ELISA plate (U96
Maxisorp, Nunc) at 4C for 16 hr. Plates were then blocked with 200 ml of PBS/
1%BSA at 37C for 1 hr. Titrated amounts of the conformationally dependent,
constant domain-reactive mAb 12H8 were then added, after which HRP-
conjugated anti-mouse Ig was added. O-phenylenediamine substrate (Sigma)
was added next and the reaction was terminated with HCl, and ELISA plates
were read at 492 nm on a Labsystems Multiscan ELISA plate reader.
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